Affordable Access

Monitoring malignant melanoma with the S-100B tumour marker.

Authors
Type
Published Article
Journal
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
Publication Date
Volume
158
Pages
149–157
Identifiers
PMID: 11092042
Source
Medline

Abstract

To assess the usefulness of the S-100B tumour marker in monitoring therapy and during follow-up we measured S-100B serum concentration in 31 patients participating in a phase I trial studying the effect of vaccination with GM-CSF gene-transduced autologous tumour cells. The S-100B serum concentration before treatment is a strong independent prognostic factor for survival, as in this study the 11 patients with low (< 0.16 microgram/l) S-100B levels were at considerably lower risk for death. All patients alive at the end of the study (n = 8) had a S-100B level within the reference range at the start of the study. At a level of 0.16 microgram/l the presence of disease could be predicted with 99% certainty for 63% of the patients. Nine patients became progressive after a stable disease. In four of them S-100 increased over 50% before clinical observation of progression, giving a lead time of more than a month in 44% of cases. In patients who acquired a status of no clinical evidence of disease after treatment, the S-100B concentration invariably decreased by more than 100%.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F